A matrix metalloproteinase 1-cleavable composite peptide derived from transforming growth factor β-inducible gene h3 potently inhibits collagen-induced arthritis

Arthritis and Rheumatism

Volumn 65, Issue 7, 2013, Pages 1753-1763

  Nam, Eon Jeong ^a   Kang, Jin Hee ^a   Sung, Shijin ^a   Sa, Keum Hee ^a   Kim, Kyung Hoon ^a   Seo, Jae Seok ^a   Kim, Jong Ho ^b   Han, Seung Woo ^a   Kim, In San ^a,b   Kang, Young Mo ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BETA IG H3 PROTEIN; COLLAGEN; DHFAS 1 PROTEIN; FAS ANTIGEN; INTERSTITIAL COLLAGENASE; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN 3T3; CELL SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACELLULAR MATRIX; GENE REPRESSION; GENE SEQUENCE; HUMAN; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SYNOVIOCYTE; SYNOVIUM; TARGET ORGAN; TREATMENT DURATION;

AMINO ACID MOTIFS; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL ADHESION; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MALE; MATRIX METALLOPROTEINASE 13; MICE; NIH 3T3 CELLS; OLIGOPEPTIDES; PEPTIDES; PRODRUGS; PROTEIN STRUCTURE, TERTIARY; SYNOVIAL MEMBRANE; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 84879858989     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37932     Document Type: Article

References (45)

1. Tak PP, Bresnihan B,. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis [review]. Arthritis Rheum 2000; 43: 2619-33.
2. Koch AE,. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 2000; 59: 65-71.
3. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T,. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 669-75.
4. Firestein GS,. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? [review]. Arthritis Rheum 1996; 39: 1781-90.
5. Barilla ML, Carsons SE,. Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum 2000; 29: 252-65.
6. Shiozawa K, Hino K, Shiozawa S,. Alternatively spliced EDA-containing fibronectin in synovial fluid as a predictor of rheumatoid joint destruction. Rheumatology (Oxford) 2001; 40: 739-42.
7. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci 2002; 99: 4556-61.
8. McInnes IB, Schett G,. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42.
9. Nam EJ, Sa KH, You DW, Cho JH, Seo JS, Han SW, et al. Up-regulated transforming growth factor β-inducible gene h3 in rheumatoid arthritis mediates adhesion and migration of synoviocytes through αvβ3 integrin: regulation by cytokines. Arthritis Rheum 2006; 54: 2734-44.
10. Kim JE, Kim SJ, Lee BH, Park RW, Kim KS, Kim IS,. Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-β-induced gene, βig-h3. J Biol Chem 2000; 275: 30907-15.
11. Kim JE, Jeong HW, Nam JO, Lee BH, Choi JY, Park RW, et al. Identification of motifs in the fasciclin domains of the transforming growth factor-β-induced matrix protein βig-h3 that interact with the αvβ5 integrin. J Biol Chem 2002; 277: 46159-65.
12. Nam JO, Kim JE, Jeong HW, Lee SJ, Lee BH, Choi JY, et al. Identification of the αvβ3 integrin-interacting motif of βig-h3 and its anti-angiogenic effect. J Biol Chem 2003; 278: 25909.
13. 2, promotes monocytes adhesion, migration and chemotaxis. Int J Biochem Cell Biol 2008; 40: 991-1004.
14. Kim JE, Kim SJ, Jeong HW, Lee BH, Choi JY, Park RW, et al. RGD peptides released from βig-h3, a TGF-β-induced cell-adhesive molecule, mediate apoptosis. Oncogene 2003; 22: 2045-53.
15. Kim HJ, Kim PK, Bae SM, Son HN, Thoudam DS, Kim JE, et al. Transforming growth factor-β-induced protein (TGFBIp/βig-h3) activates platelets and promotes thrombogenesis. Blood 2009; 114: 5206-15.
16. Kawamoto T, Noshiro M, Shen M, Nakamasu K, Hashimoto K, Kawashima-Ohya Y, et al. Structural and phylogenetic analyses of RGD-CAP/βig-h3, a fasciclin-like adhesion protein expressed in chick chondrocytes. Biochim Biophys Acta 1998; 1395: 288-92.
17. Ruoslahti E,. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996; 12: 697-715.
18. Malemud CJ,. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006; 11: 1696-701.
19. Rannou F, Francois M, Corvol MT, Berenbaum F,. Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine 2006; 73: 29-36.
20. Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL,. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 1995; 54: 25-32.
21. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59: 455-61.
22. Nagase H,. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60.
23. Brownlie RJ, Myers LK, Wooley PH, Corrigall VM, Bodman-Smith MD, Panayi GS, et al. Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4- producing regulatory T cells: a novel function for an ancient protein. Arthritis Rheum 2006; 54: 854-63.
24. Nam JO, Jeong HW, Lee BH, Park RW, Kim IS,. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of βig-h3, via αvβ3 integrin. Cancer Res 2005; 65: 4153-61.
25. Verheijen JH, Nieuwenbroek NM, Beekman B, Hanemaaijer R, Verspaget HW, Ronday HK, et al. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J 1997; 323: 603-9.
26. Clemmensen I, Holund B, Andersen RB,. Fibrin and fibronectin in rheumatoid synovial membrane and rheumatoid synovial fluid. Arthritis Rheum 1983; 26: 479-85.
27. Nikkari L, Haapasalmi K, Aho H, Torvinen A, Sheppard D, Larjava H, et al. Localization of the αv subfamily of integrins and their putative ligands in synovial lining cell layer. J Rheumatol 1995; 22: 16-23.
28. Pardo A, Selman M,. MMP-1: the elder of the family. Int J Biochem Cell Biol 2005; 37: 283-8.
29. Woolley DE, Crossley MJ, Evanson JM,. Collagenase at sites of cartilage erosion in the rheumatoid joint. Arthritis Rheum 1977; 20: 1231-9.
30. Okada Y, Gonoji Y, Nakanishi I, Nagase H, Hayakawa T,. Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium. Virchows Arch B Cell Pathol Incl Mol Pathol 1990; 59: 305-12.
31. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 83-8.
32. Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002; 4 Suppl 3: S39-49.
33. Jackson CJ, Arkell J, Nguyen M,. Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1). Ann Rheum Dis 1998; 57: 158-61.
34. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY,. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996; 134: 793-9.
35. Brooks PC, Clark RA, Cheresh DA,. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994; 264: 569-71.
36. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA,. Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist. J Clin Invest 1999; 103: 47-54.
37. Noiri E, Goligorsky MS, Wang GJ, Wang J, Cabahug CJ, Sharma S, et al. Biodistribution and clearance of 99mTc-labeled Arg-Gly-Asp (RGD) peptide in rats with ischemic acute renal failure. J Am Soc Nephrol 1996; 7: 2682-8.
38. Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, et al. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer 2002; 102: 469-75.
39. Garamszegi N, Garamszegi SP, Scully SP,. Matrix metalloproteinase-1 contribution to sarcoma cell invasion. J Cell Mol Med 2012; 16: 1331-41.
40. Hu J, Van den Steen PE, Sang QX, Opdenakker G,. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6: 480-98.
41. Ryu JH, Lee A, Chu JU, Koo H, Ko CY, Kim HS, et al. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe. Arthritis Rheum 2011; 63: 3824-32.
42. Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 2003; 63: 4062-6.
43. Wythe SE, DiCara D, Taher TE, Finucane CM, Jones R, Bombardieri M, et al. Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide. Ann Rheum Dis 2013; 72: 129-35.
44. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Therapy 2009; 11: R142.
45. Crielaard BJ, Lammers T, Schiffelers RM, Storm G,. Drug targeting systems for inflammatory disease: one for all, all for one. J Control Release 2012; 161: 225-34.